Digital Content 
NEWS #PharmaBuzz
29 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/menarini-anuncia-datos-positivos-del-ensayo-clinico-fundamental-de-fase-3-brooklyn-302209004.html
08 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/08/2909562/0/en/NewAmsterdam-Pharma-Completes-Enrollment-in-Pivotal-Phase-3-TANDEM-Clinical-Trial-Evaluating-Fixed-Dose-Combination-of-Obicetrapib-plus-Ezetimibe-in-Patients-with-HeFH-and-or-ASCVD.html
11 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/11/2896737/0/en/NewAmsterdam-Pharma-Announces-Issuance-of-Composition-of-Matter-Patent-for-Obicetrapib-by-the-United-States-Patent-and-Trademark-Office.html
21 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/21/2885534/0/en/NewAmsterdam-Pharma-to-Present-New-Clinical-and-Preclinical-Data-Highlighting-Obicetrapib-s-Impact-on-Key-Risk-Factors-for-Cardiovascular-Disease-at-Upcoming-Medical-Meetings.html
09 Apr 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/04/09/2859907/0/en/NewAmsterdam-Pharma-Enrolls-Over-9-000-Patients-in-Pivotal-Phase-3-PREVAIL-Global-Cardiovascular-Outcome-Trial-Evaluating-the-Effect-of-Obicetrapib-in-Patients-with-Established-Ath.html
12 Mar 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/03/12/2844471/0/en/NewAmsterdam-Pharma-Doses-First-Patient-in-Phase-3-TANDEM-Clinical-Trial-Evaluating-Fixed-Dose-Combination-of-Obicetrapib-and-Ezetimibe-in-Patients-with-HeFH-and-or-ASCVD.html
LOOKING FOR A SUPPLIER?
Share